About Dottikon
Dottikon is a publicly listed company based in Bremgarten (Switzerland) founded in 1913. Hazardous reactions are utilized for API and intermediate manufacturing. Dottikon offers products and services including Exclusive Synthesis, Active Pharmaceutical Ingredients, and Performance Chemicals. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and API Production. Its legal entity is DOTTIKON ES AMERICA INC.
Company details
Dottikon Exclusive Synthesis manufactures exclusive active pharmaceutical ingredients (APIs), high-quality intermediates and performance chemicals for chemical and pharmaceutical companies. The company with its production site in Dottikon (Aargau, Switzerland) is specialised in hazardous reactions and is positioned as a strategic development and manufacturing partner for APIs. Its core expertise lies in its capabilities for performing hazardous reactions (involving highly exothermic processes, highly reactive compounds, thermally or mechanically unstable compounds or mixtures and highly active and highly potent APIs), and techniques, equipment and processes that employ low-temperature, high-pressure chemistry and continuous processing. Dottikon claims that its safety lab applies 14 proprietary tests to gather safety data for the development of APIs. The company claims that all these can shorten conventional chemical synthesis routes, increase yields, selectivities and purities, improve safety and reduce waste. The technology and equipment portfolio is used to design, develop and optimise chemical processes, and scale up from kgs to multi-tons. Dottikon also offers custom synthesis and project management services for the development of new substances and products.
- Headquarters Bremgarten, Switzerland
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website dottikon.com
- Social LinkedIn Facebook Instagram
- Legal Name Dottikon Es Holding Ag
- Annual Revenue$535.78 M (USD)11.23as on Mar 31, 2026
- Net Profit$129.56 M (USD)-1.87as on Mar 31, 2026
- EBITDA$183.36 M (USD)5.61as on Mar 31, 2026
Products & Services of Dottikon
Dottikon offers a comprehensive portfolio of products and services, including Exclusive Synthesis, Active Pharmaceutical Ingredients, and Performance Chemicals.
Provides synthesis of APIs and chemicals for pharmaceutical applications.
Manufactures high-quality APIs for biotech and chemical industries worldwide.
Offers specialized chemicals for various industrial and biotech uses.
People of Dottikon
8 people are tracked at Dottikon (6 in leadership, 2 in board & advisors).
| Name | Role | Group |
|---|---|---|
Marlene Born | CFO | Leadership |
Markus Blocher | CEO | Leadership |
Stephan Kirschbaum | Head of Business Development | Leadership |
Karin Krause | Head of Human Resources | Leadership |
Robert Dahinden | Head of Production | Leadership |
Thomas Rosatzin | Head of Purchasing | Leadership |
Alfred Scheidegger | Deputy Chairman | Board & advisors |
Bernhard Urwyler | Director | Board & advisors |
Complete people profiles for Dottikon
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Dottikon
Dottikon is a publicly listed company on the SIX with ticker symbol DESN in Switzerland, operating in the Process industries sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date31 Mar 2005
- Listed onSWX: DESN
- Listed entityDottikon ES Holding AG
- Exchange sectorProcess industries
- ISINCH0582581713
- Share price359.50 CHF (-0.28% on the day) · 2026-05-11
- Market capitalisation4,982,003,656.00 CHF
- Price to earnings41.1
- EPS (diluted, trailing year)8.75 CHF
- Volume (last session)608
- Analyst consensusNeutral
Financials of Dottikon
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 428.4M CHF | 103.6M CHF | 146.6M CHF |
| 2024 | 385.2M CHF | 105.6M CHF | 138.8M CHF |
| 2023 | 326.2M CHF | 80.6M CHF | 109.7M CHF |
| 2022 | 319.4M CHF | 87.7M CHF | 120.6M CHF |
| 2021 | 251.9M CHF | 59.3M CHF | 98.2M CHF |
Detailed financial statements for Dottikon
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Web traffic of Dottikon
The website of Dottikon (dottikon.com) receives about 7.9K visits a month.
- Monthly visits7.9K
▲ 11% vs previous month
Websites whose visitors overlap most with Dottikon. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| ems-group.com | 70% | 24.7K | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Dottikon
Complete news archive for Dottikon
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Dottikon
Dottikon was founded in 1913.
Dottikon is headquartered in Bremgarten, Switzerland. It is registered at Bremgarten, Aargau, Switzerland.
Annual revenue of Dottikon is $535.78M as on Mar 31, 2026.
Dottikon Exclusive Synthesis manufactures exclusive active pharmaceutical ingredients (APIs), high-quality intermediates and performance chemicals for chemical and pharmaceutical companies. The company with its production site in Dottikon (Aargau, Switzerland) is specialised in hazardous reactions and is positioned as a strategic development and manufacturing partner for APIs. Its core expertise lies in its capabilities for performing hazardous reactions (involving highly exothermic processes, highly reactive compounds, thermally or mechanically unstable compounds or mixtures and highly active and highly potent APIs), and techniques, equipment and processes that employ low-temperature, high-pressure chemistry and continuous processing. Dottikon claims that its safety lab applies 14 proprietary tests to gather safety data for the development of APIs. The company claims that all these can shorten conventional chemical synthesis routes, increase yields, selectivities and purities, improve safety and reduce waste. The technology and equipment portfolio is used to design, develop and optimise chemical processes, and scale up from kgs to multi-tons. Dottikon also offers custom synthesis and project management services for the development of new substances and products.
Dottikon offers Exclusive Synthesis, Active Pharmaceutical Ingredients, and Performance Chemicals.
Yes, Dottikon is publicly traded on SIX under the ticker symbol DESN.
Dottikon operates through Dottikon Es America Inc.